EXACT Sciences Receives Average Rating of “Hold” from Analysts (NASDAQ:EXAS)
EXACT Sciences (NASDAQ:EXAS) has been given a consensus rating of “Hold” by the ten ratings firms that are currently covering the company, Analyst Ratings Network.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $21.00.
Several analysts have recently commented on the stock. Analysts at JMP Securities raised their price target on shares of EXACT Sciences from $22.00 to $28.00 in a research note on Wednesday, August 27th. They now have a “market outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $21.00 to $23.00 in a research note on Tuesday, August 26th. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, August 12th. They now have a $20.00 price target on the stock, up previously from $19.00.
Shares of EXACT Sciences (NASDAQ:EXAS) opened at 20.85 on Tuesday. EXACT Sciences has a one year low of $9.53 and a one year high of $22.25. The stock’s 50-day moving average is $17.50 and its 200-day moving average is $14.83. The company’s market cap is $1.729 billion. EXACT Sciences also was the target of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 26,442,496 shares, an increase of 4.9% from the July 31st total of 25,198,205 shares. Based on an average daily volume of 2,400,773 shares, the short-interest ratio is currently 11.0 days. Approximately 32.4% of the shares of the company are sold short.
EXACT Sciences (NASDAQ:EXAS) last released its earnings data on Tuesday, July 22nd. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Receive News & Ratings for EXACT Sciences Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co and related companies with Analyst Ratings Network's FREE daily email newsletter.